Abraxane Side Effects
Abraxane |
Protein-bound paclitaxel may cause
side effects:
- pain, redness, swelling, or sores in the place where the medication was injected
- weakness
- muscle or joint pain
- nausea
- vomiting
- diarrhea
- stomach pain
- sores in the mouth
- hair loss
Some side effects can be serious:
- numbness, burning, or tingling in the hands or feet
- pale skin
- excessive tiredness
- unusual bruising or bleeding
- chest pain
- slow or irregular heartbeat
- fainting
- hardening, darkening, or peeling of the skin in the area where the medication was injected
- blistering or peeling skin
There is an associated “black box” warning attached to this drug. Protein-bound paclitaxel particles therapy is usually forbidden from being administered to patients with metastatic breast cancer who’ve got a baseline neutrophils count of less than 1500 cells/mm. In addition to that, it is further recommended that frequent peripheral blood cell counts should be performed on all patients to monitor for the occurrence of suppression of bone marrow. Furthermore, albumin formulations can substantially affect functional properties relative to solution formulations of this drug.If you or a loved one has suffered serious adverse reactions as a result of taking this drug, please do not hesitate to
contact someone who can help you.
Warnings & Recalls for Abraxane
The most common contraindications of
Abraxane |
Protein-bound paclitaxel is the associated warning of administering it to patients who’ve got a baseline neutrophils count of less than 1500 cells/mm who also have metastatic breast cancer, and those patients who have a hypersensitivity to the active ingredient in this drug, paclitaxel.Also, male patients are advised not to sire or father any children while taking this drug. Women of child-bearing potential are especially dissuaded from taking this drug due to serious harm to the fetus, which can also include death of the fetus.If you or a loved one has suffered serious adverse reactions as a result of taking this drug, please do not hesitate to
contact someone who can help you.
Abraxane Treatment and Use
Abraxane | Protein-bound paclitaxel is an injectable drug that is used in the treatment of breast cancer. Abraxane | Protein-bound paclitaxel’s drug classification is that of a mitotic inhibitor drug and comes exclusively in injectable form. In the US, it was marketed by the drug company Abraxis BioScience however is now been acquired by Celgene in 2010. This specific formulation is bonded to albumin as a method of delivery to treat breast cancer.
This drug was first approved by the FDA in January of 2005 for cases of breast cancer where therapy hadn’t yielded formative or desirable results during chemotherapy or when the cancer had relapsed. Abraxane | Protein-bound paclitaxel is the first in its class of drugs to be using a nanoparticle albumin bound technology platform.
The non-FDA labeled indications for Abraxane | Protein-bound paclitaxel are:
- Anal cancer
- Head and neck cancer
- Non-small cell lung cancer
Total sales revenue from the drug Abraxane | Protein-bound paclitaxel in 2009 was $314.5 million.
There is an associated “black box” warning attached to this drug. Protein-bound paclitaxel particles therapy is usually forbidden from being administered to patients with metastatic breast cancer who’ve got a baseline neutrophils count of less than 1500 cells/mm. In addition to that, it is further recommended that frequent peripheral blood cell counts should be performed on all patients to monitor for the occurrence of suppression of bone marrow. Furthermore, albumin formulations can substantially affect functional properties relative to solution formulations of this drug.
If you or a loved one has suffered serious adverse reactions as a result of taking this drug, please do not hesitate to contact someone who can help you.
